P-277 A prospective, observational trial to assess the safety and efficacy of regorafenib in patients with metastatic colorectal cancer (mCRC) in routine clinical practice (CORRELATE)

Lignende værker

• PD-003 Analysis of single-nucleotide polymorphisms (SNPs) in the phase 3 CORRECT trial of regorafenib vs placebo in patients with metastatic colorectal cancer (mCRC)
  af: Lambrechts, D., et al.
  Udgivet: (2016)
• Factors influencing choice of chemotherapy in metastatic colorectal cancer (mCRC)
  af: Rossi, Luigi, et al.
  Udgivet: (2013)
• Bevacizumab as maintenance therapy in mCRC: Interpreting results of the MOMA trial
  af: Marmorino, Federica, et al.
  Udgivet: (2019)
• PD-012 Analysis of patients ≥75 years in the open-label phase 3b CONSIGN trial of regorafenib in previously treated metastatic colorectal cancer (mCRC)
  af: Van Cutsem, E., et al.
  Udgivet: (2016)
• Anti-VEGF agents in metastatic colorectal cancer (mCRC): are they all alike?
  af: Saif MW
  Udgivet: (2013-06-01)